IMAC HOLDINGS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.17 USD | +2.26% |
|
+2.28% | +42.54% |
Financials (USD)
| Sales 2024 * | 4.2M | Sales 2025 * | - | Capitalization | 3.56M |
|---|---|---|---|---|---|
| Net income 2024 * | -2M | Net income 2025 * | - | EV / Sales 2024 * | 0.85 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.29
x | P/E ratio 2025 * |
-
| Employees | 85 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.44% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.26% | ||
| 1 week | +2.28% | ||
| Current month | +2.94% | ||
| 1 month | +140.47% | ||
| 3 months | +55.95% | ||
| 6 months | +67.02% | ||
| Current year | +42.54% |
1 week
2.93
4.85
1 month
1.264.85
Current year
1.224.85
1 year
1.226.29
3 years
1.2282.50
5 years
1.22165.00
10 years
1.22216.15
| Managers | Title | Age | Since |
|---|---|---|---|
Jeffrey Ervin
CEO | Chief Executive Officer | 46 | 15-02-28 |
Matthew Wallis
FOU | Founder | 50 | 00-07-31 |
Sheri Gardzina
DFI | Director of Finance/CFO | 55 | 17-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Pruitt
BRD | Director/Board Member | 64 | 20-10-20 |
Cary Sucoff
BRD | Director/Board Member | 71 | 20-10-20 |
Jeffrey Ervin
CEO | Chief Executive Officer | 46 | 15-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 3.15 | +1.62% | 48 391 |
| 24-04-18 | 3.1 | -12.68% | 99,163 |
| 24-04-17 | 3.55 | -21.81% | 283,535 |
| 24-04-16 | 4.54 | +35.52% | 972,000 |
| 24-04-15 | 3.35 | +8.77% | 439,632 |
Delayed Quote Nasdaq, April 19, 2024 at 03:04 pm EDT
More quotes
IMAC Holdings, Inc. owns and manages health and wellness centers that delivers sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases. The Company provides movement, orthopedic and neurological therapies through its chain of Innovative Medical Advancements and Care (IMAC) Regeneration Centers. The Company, through its outpatient medical clinics, provide conservative, minimally invasive medical treatments to help patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. It operates through two business segments: outpatient medical centers and clinical research division. The Company's research division is conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinson's disease. The Company operates approximately 10 outpatient medical clinics in five states in the United States.
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.1
USD
Average target price
10
USD
Spread / Average Target
+222.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +42.54% | 3.56M | |
| -23.26% | 16.01B | |
| 0.00% | 12.09B | |
| +1.49% | 11.21B | |
| +8.16% | 10.45B | |
| +18.71% | 7.87B | |
| -4.79% | 7.45B | |
| +22.00% | 7.27B | |
| +5.17% | 6.63B | |
| -1.16% | 4.42B |
- Stock Market
- Equities
- BACK Stock
